Cipla has allotted 2484 equity shares under ESOS. Consequently, the issued, subscribed and paid-up share capital of the Company standsincreased to Rs. 1 ,61 ,24,55, 192 /- comprising of 80,62,27,596 equity shares of face valueRs.2/- each.

Powered by Capital Market - Live News

Avenue Therapeutics (an associate company of Cipla), a company focused on the development of intravenous (IV) tramadol for the U.S. market, on 11 December 2019 announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for IV tramadol for the management of moderate to moderately severe pain in adults in a medically supervised health care setting.

Powered by Capital Market - Live News

Cipla announced that its wholly owned subsidiary, Cipla (EU), holding 60% stake in Cipla Pharma Lanka, Sri Lanka, has signed an agreement with CitiHealth Imports to acquire the remaining 40% stake in Cipla Pharma Lanka. Post acquisition, Cipla Lanka will become a wholly owned subsidiary.

Powered by Capital Market - Live News

Cipla Ltd is up for a third straight session today. The stock is quoting at Rs 487.8, up 1.08% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.05% on the day, quoting at 11993.5. The Sensex is at 40640.4, down 0.03%. Cipla Ltd has gained around 7.47% in last one month.

Meanwhile, Nifty Pharma index of which Cipla Ltd is a constituent, has gained around 4.51% in last one month and is currently quoting at 8107.6, down 0.15% on the day. The volume in the stock stood at 40.64 lakh shares today, compared to the daily average of 41.47 lakh shares in last one month.

The benchmark November futures contract for the stock is quoting at Rs 487.9, up 1.14% on the day. Cipla Ltd is down 5.82% in last one year as compared to a 13.93% jump in NIFTY and a 12.97% jump in the Nifty Pharma index.

The PE of the stock is 16.48 based on TTM earnings ending September 19.

Powered by Capital Market - Live News